Humoral Response to Hepatitis B and COVID-19 Vaccine among Maintenance Hemodialysis Patients

Humoral Response to Hepatitis B and COVID-19 Vaccine among Maintenance Hemodialysis Patients

Maintenance hemodialysis (MHD) patients have impaired immunological responses to pathogens and vaccines. In this study, we compared the humoral response to HBV and COVID-19 vaccines in a cohort of MHD patients. Demographic and clinical characteristics of vaccine responders and non-responders were al...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) Vol. 10; no. 10; p. 1670
Main Authors: Nacasch, Naomi, Cohen-Hagai, Keren, Tayar, Nurit, Levian, Avraham, Rashid, Gloria, Benchetrit, Sydney, Neumark, Eran, Wand, Ori, Hod, Tammy, Rosman, Yossi, Shashar, Moshe, Grupper, Ayelet, Shitrit, Pnina
Format: Journal Article
Language:English
Published: Basel MDPI AG 01-10-2022
MDPI
Subjects:
Cardiovascular disease
Cardiovascular diseases
Congestive heart failure
Coronary artery disease
Coronaviruses
COVID-19
COVID-19 vaccine
COVID-19 vaccines
Dosage and administration
Evaluation
Heart diseases
Hemodialysis
Hemodialysis patients
Hepatitis
Hepatitis B
Hepatitis B vaccine
humoral response
Hypertension
Immune response
Immune response (humoral)
Immune system
Immunoglobulin G
Immunology
Immunosuppressive agents
Maintenance
Patient outcomes
Patients
Risk analysis
Severe acute respiratory syndrome coronavirus 2
Vaccines
Israel
United States > US
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Maintenance hemodialysis (MHD) patients have impaired immunological responses to pathogens and vaccines. In this study, we compared the humoral response to HBV and COVID-19 vaccines in a cohort of MHD patients. Demographic and clinical characteristics of vaccine responders and non-responders were also compared, and the association between the humoral responses to both vaccines was evaluated. The cohort included 94 MHD patients who were vaccinated at least once for HBV and twice for COVID-19. Among the 94 patients, 28 (29.8%) did not develop protective titers to HBV. Hypertension, coronary heart disease, and heart failure were more common in non-responders. Among MHD patients, 85% had positive IgG anti-spike SARS-CoV-2 levels 6 months after two doses of BNT162b2 (Pfizer/Biotech) vaccine. Age and immunosuppressive therapy were the main predictors of humoral response to COVID-19 vaccine. We did not find any association between non-responders to HBV and non-responders to COVID-19 vaccine. There was no difference in IgG anti-spike titers between HBV responders and non-responders (505 ± 644 vs. 504 ± 781, p = 0.9) Our results suggest that reduced humoral response to hepatitis B is not associated with reduced response to COVID-19 vaccine. Different risk-factors were associated with poor immune response to HBV and to COVID-19 vaccines.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines10101670